| Company Name: |
TargetMol |
| Tel: |
400-821-0310 15002144251 |
| Email: |
xuexiang.shao@tsbiochem.com |
|
| | 9-tert-butyl doxycycline HCL Basic information |
| Product Name: | 9-tert-butyl doxycycline HCL | | Synonyms: | 9-tert-butyl doxycycline HCL;2-Naphthacenecarboxamide, 4-(dimethylamino)-9-(1,1-dimethylethyl)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-;9-tert-Butyldoxycycline | | CAS: | 233585-94-9 | | MF: | C26H32N2O8 | | MW: | 500.54 | | EINECS: | | | Product Categories: | | | Mol File: | 233585-94-9.mol |  |
| | 9-tert-butyl doxycycline HCL Chemical Properties |
| Boiling point | 759.6±60.0 °C(Predicted) | | density | 1.49±0.1 g/cm3(Predicted) | | pka | 4.50±1.00(Predicted) |
| | 9-tert-butyl doxycycline HCL Usage And Synthesis |
| Uses | 9-tert-Butyldoxycycline exhibits immunomodulatory activity, alters the polarization states polymorphonuclear neutrophils, and ameliorates the inflammatory response in ischemia-reperfusion injury model. 9-tert-Butyldoxycycline is the ligand for ‘Tet-On’ switch system[1][2]. | | References | [1] Mai N, et al., Effects of 9-t-butyl doxycycline on the innate immune response to CNS ischemia-reperfusion injury. Exp Mol Pathol. 2021 Feb;118:104601. DOI:10.1016/j.yexmp.2020.104601 |
| | 9-tert-butyl doxycycline HCL Preparation Products And Raw materials |
|